STADA Arzneimittel Aktiengesellschaft
STADA Arzneimittel Aktiengesellschaft, commonly known as STADA, is a prominent player in the global pharmaceutical industry, headquartered in Bad Vilbel, Germany. Founded in 1895, the company has established a strong presence in Europe and beyond, focusing on the development, manufacturing, and marketing of generic and over-the-counter (OTC) products. STADA's core offerings include a diverse range of pharmaceuticals, particularly in the fields of pain management, dermatology, and respiratory health. The company is recognised for its commitment to quality and innovation, which has positioned it as a trusted provider in the healthcare sector. With a robust portfolio and a strategic focus on expanding its market reach, STADA continues to achieve significant milestones, reinforcing its status as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does STADA Arzneimittel Aktiengesellschaft's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
STADA Arzneimittel Aktiengesellschaft's score of 33 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
STADA Arzneimittel Aktiengesellschaft's reported carbon emissions
In 2023, STADA Arzneimittel Aktiengesellschaft reported total carbon emissions of approximately 99238000 kg CO2e, comprising 42696000 kg CO2e from Scope 1, 56542000 kg CO2e from Scope 2, and a significant 900000000 kg CO2e from Scope 3 emissions. This indicates a substantial reliance on indirect emissions, which are often the largest contributor in the pharmaceutical sector. Comparatively, in 2022, the company emitted about 109954000 kg CO2e, with Scope 1 and 2 emissions totalling 109954000 kg CO2e, highlighting a slight increase in overall emissions year-on-year. In 2021, STADA's emissions were approximately 114781000 kg CO2e, while in 2020, they reported 131619000 kg CO2e. This trend suggests a need for enhanced strategies to manage and reduce emissions effectively. STADA has committed to near-term climate targets, although specific reduction targets have not been disclosed. The company is actively engaged in sustainability initiatives within the pharmaceuticals, biotechnology, and life sciences sector, indicating a recognition of the importance of addressing climate change. However, they have not yet committed to a net-zero target. Overall, STADA's emissions data reflects the challenges faced by the pharmaceutical industry in reducing carbon footprints, particularly in managing Scope 3 emissions, which often represent the majority of total emissions. The company's ongoing commitment to sustainability will be crucial in navigating these challenges and achieving future emissions reductions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 38,202,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 93,417,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
STADA Arzneimittel Aktiengesellschaft is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
